Literature DB >> 33422864

Willingness to initiate pre-exposure prophylaxis (PrEP) and its use among opioid-dependent individuals in drug treatment.

Zhao Ni1, Frederick L Altice2, Jeffrey A Wickersham3, Michael M Copenhaver4, Elizabeth E DiDomizio5, LaRon E Nelson6, Roman Shrestha3.   

Abstract

BACKGROUND: People who use drugs (PWUD) continue to experience a disproportionate HIV burden due to drug- and sex-related risk behaviors. Pre-exposure prophylaxis (PrEP) is highly effective at preventing HIV infection, but very little is known about PrEP use among PWUD and their willingness to initiate PrEP.
METHODS: We conducted a cross-sectional survey among 234 HIV-negative, opioid-dependent individuals recruited from an urban methadone clinic. Participants were assessed using an audio-computer assisted self-interview technique. Bivariate and multiple logistic regressions were used to explore independent correlates of actual PrEP use and willingness to initiate PrEP.
RESULTS: One-fourth (25.6 %) of participants had previously used PrEP. Over two-thirds (67.1 %) of participants had previously heard of PrEP, and 65.0 % were willing to take it. In multivariable logistic regression analyses, the number of times participants engaged in HIV testing (aOR = 1.66, p < 0.01) and whether they visited a healthcare provider (aOR=20.81, p = 0.02) were associated with a higher likelihood of PrEP use, while perceived HIV risk (aOR=2.71, p < 0.01) and previous use of PrEP (aOR=3.57, p < 0.01) were significantly associated with willingness to initiate PrEP.
CONCLUSION: PrEP use was low among PWUD, but their willingness to initiate PrEP was moderate, which indicated a significant discrepancy between actual PrEP use and willingness to use it. Our findings highlight the importance of healthcare providers engaging opioid-dependent individuals in discussions about PrEP and the need for innovative strategies to increase their awareness of PrEP and modify their perceptions of HIV risk.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  HIV prevention; Opioid use disorder; Opioid-dependent; People who use drugs (PWUD); Pre-exposure prophylaxis (PrEP); Sexual risk behavior; Substance use

Mesh:

Substances:

Year:  2021        PMID: 33422864      PMCID: PMC7946167          DOI: 10.1016/j.drugalcdep.2020.108477

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  33 in total

1.  Accessibility and utilization patterns of a mobile medical clinic among vulnerable populations.

Authors:  Britton A Gibson; Debarchana Ghosh; Jamie P Morano; Frederick L Altice
Journal:  Health Place       Date:  2014-05-21       Impact factor: 4.078

2.  Correlates of willingness to initiate pre-exposure prophylaxis and anticipation of practicing safer drug- and sex-related behaviors among high-risk drug users on methadone treatment.

Authors:  Roman Shrestha; Pramila Karki; Frederick L Altice; Tania B Huedo-Medina; Jaimie P Meyer; Lynn Madden; Michael Copenhaver
Journal:  Drug Alcohol Depend       Date:  2017-02-02       Impact factor: 4.492

3.  Measuring Acceptability and Preferences for Implementation of Pre-Exposure Prophylaxis (PrEP) Using Conjoint Analysis: An Application to Primary HIV Prevention Among High Risk Drug Users.

Authors:  Roman Shrestha; Pramila Karki; Frederick L Altice; Oleksandr Dubov; Liana Fraenkel; Tania Huedo-Medina; Michael Copenhaver
Journal:  AIDS Behav       Date:  2018-04

4.  Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.

Authors:  Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

5.  Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs.

Authors:  Roman Shrestha; Elizabeth E DiDomizio; Rayne S Kim; Frederick L Altice; Jeffrey A Wickersham; Michael M Copenhaver
Journal:  J Subst Abuse Treat       Date:  2020-06-15

6.  Sexual violence among a cohort of injection drug users.

Authors:  Paula Braitstein; Kathy Li; Mark Tyndall; Patricia Spittal; Michael V O'Shaughnessy; Arn Schilder; Caitlin Johnston; Robert S Hogg; Martin T Schechter
Journal:  Soc Sci Med       Date:  2003-08       Impact factor: 4.634

7.  Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study.

Authors:  Andreas B Eisingerich; Ana Wheelock; Gabriela B Gomez; Geoffrey P Garnett; Mark R Dybul; Peter K Piot
Journal:  PLoS One       Date:  2012-01-11       Impact factor: 3.240

8.  Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study.

Authors:  Lucas Wiessing; Marica Ferri; Vendula Běláčková; Patrizia Carrieri; Samuel R Friedman; Cinta Folch; Kate Dolan; Brian Galvin; Peter Vickerman; Jeffrey V Lazarus; Viktor Mravčík; Mirjam Kretzschmar; Vana Sypsa; Ana Sarasa-Renedo; Anneli Uusküla; Dimitrios Paraskevis; Luis Mendão; Diana Rossi; Nadine van Gelder; Luke Mitcheson; Letizia Paoli; Cristina Diaz Gomez; Maitena Milhet; Nicoleta Dascalu; Jonathan Knight; Gordon Hay; Eleni Kalamara; Roland Simon; Catherine Comiskey; Carla Rossi; Paul Griffiths
Journal:  Harm Reduct J       Date:  2017-04-22

9.  Pre-exposure prophylaxis (PrEP) for MSM in low HIV incidence places: should high risk individuals be targeted?

Authors:  Ngai Sze Wong; Tsz Ho Kwan; Owen T Y Tsang; Man Po Lee; Wing Cheong Yam; Wilson Lam; Wai Shing Leung; Jacky M C Chan; Kai Man Ho; Shui Shan Lee
Journal:  Sci Rep       Date:  2018-08-03       Impact factor: 4.379

10.  Acceptability of HIV self-testing to support pre-exposure prophylaxis among female sex workers in Uganda and Zambia: results from two randomized controlled trials.

Authors:  Katrina F Ortblad; Michael M Chanda; Daniel Kibuuka Musoke; Thomson Ngabirano; Magdalene Mwale; Aidah Nakitende; Steven Chongo; Nyambe Kamungoma; Catherine Kanchele; Till Bärnighausen; Catherine E Oldenburg
Journal:  BMC Infect Dis       Date:  2018-10-04       Impact factor: 3.090

View more
  3 in total

1.  Fentanyl Test Strip Use and Overdose History among Individuals on Medication for Opioid Use Disorder.

Authors:  C B Mistler; A O Rosen; W Eger; M M Copenhaver; R Shrestha
Journal:  Austin J Public Health Epidemiol       Date:  2021-12-29

2.  Logistical Facilitators and Barriers to PrEP Implementation in Methadone Clinic Settings: Provider and Staff Perspectives.

Authors:  Jessica Jaiswal; Marybec Griffin; Kevin Hascher; Amanda B Cox; Kandyce Dunlap; Suzan Walters; Caleb LoSchiavo; Wanda M Burton; Mercy Mumba
Journal:  J Addict Med       Date:  2022-02-14       Impact factor: 4.647

3.  Suboptimal Uptake, Retention, and Adherence of Daily Oral Prexposure Prophylaxis Among People With Opioid Use Disorder Receiving Hepatitis C Virus Treatment.

Authors:  Christopher Brokus; Sarah Kattakuzhy; Britt Gayle; Shivakumar Narayanan; Ashley Davis; Amelia Cover; Rahwa Eyasu; Emade Ebah; Onyinyechi Ogbumbadiugha-Weekes; Jennifer Hoffmann; Rachel Silk; Jasmine Stevens; Julia Mount; Catherine Gannon; Laura Nussdorf; Poonam Mathur; Phyllis Bijole; Miriam Jones; Randy Kier; David Sternberg; Aaron Greenblatt; Eric Weintraub; Henry Masur; Shyamasundaran Kottilil; Elana Rosenthal
Journal:  Open Forum Infect Dis       Date:  2021-12-29       Impact factor: 3.835

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.